EDNRA

(redirected from Endothelin A receptor)

EDNRA

A gene on chromosome 4q31.22 that encodes endothelin-A receptor, a member of the endothelin receptor group of G-protein-coupled receptors, located primarily in the vascular endothelial cells where they play a role in vasoconstriction, vasodilation, bronchoconstriction and cell proliferation.

Molecular pathology
EDNRA polymorphisms have been linked to migraine headache resistance.
Mentioned in ?
References in periodicals archive ?
Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy.
Bakris noted that Gilead Sciences made a splash earlier this year when it released interim results showing dramatic additional blood pressure reductions with its selective endothelin A receptor antagonist darusentan in patients who had resistant hypertension despite maximal doses of a three-drug regimen that included a diuretic.
Under the agreement Pfizer will acquire the rights to Thelin (sitaxsentan sodium), an oral, once-daily endothelin A receptor antagonist (ETRA) for the treatment of PAH, as well as Encysive's other pipeline candidates.
The purpose of this study was to characterize the role of endogenous ET-1 in the vascular system of poultry by investigating the effect of endothelin A receptor ([ET.
Texas Biotechnology also has two highly selective endothelin A receptor antagonists in clinical development for pulmonary arterial hypertension and congestive heart failure.
Reversal of postischemic acute renal failure with a selective endothelin A receptor antagonist in the rat.
This year another endothelin A receptor antagonist failed to demonstrate an advantage for advanced prostate cancer.
Sitaxsentan is a highly selective endothelin A receptor antagonist and is 6500 times more selective for endothelin A than endothelin B receptors.
Clinical trials are now under way with Axovan's lead product, Clazosentan, an endothelin A receptor antagonist, for the treatment of vasospasm, which occurs as a frequent and severe adverse effect after sub-arachnoid hemorrhage.
Derek's extensive background in launching new drugs, including pre-launch work on Zetia(R) and Clarinex(R), will be invaluable as we drive towards commercialization of sitaxsentan, our once daily, selective endothelin A receptor antagonist for the treatment of pulmonary arterial hypertension.
We are determined to bring patients with PAH, many of whom are children or young adults, an important alternative to current therapies, one which combines endothelin A receptor selectivity with the convenience of once daily dosing.

Full browser ?